AstraZeneca PLC - American Depositary Shares (NY:AZN)

Oncology and rare disease momentum offset cardiovascular headwinds.

Topics Earnings Intellectual Property

AstraZeneca (AZN) Q3 2026 Earnings Call Transcript ↗

October 31, 2026

AstraZeneca (NYSE:AZN) reported continued revenue and earnings growth for the first nine months of 2026, supported by double-digit expansion in oncology, rare disease and respiratory and immunology,...

Topics Earnings

AstraZeneca Q3 Earnings Call Highlights ↗

October 30, 2026

Topics ETFs Earnings

AstraZeneca results: 9M and Q3 2026

October 30, 2026

From AstraZeneca

AstraZeneca and Mark-Paul Gosselaar Launch Meet Your Mark to Raise Awareness of Cancer Biomarker Testing

October 28, 2026

From AstraZeneca

Astrazeneca (NYSE:AZN) highlighted new clinical data across bladder, lung and gastric cancers at its ESMO 2026 investor event, including four presidential presentations that executives said support the...

AstraZeneca Highlights Breakthrough Cancer Data at ESMO 2026 Investor Update ↗

October 26, 2026

Sonesitatug vedotin reduced the risk of death by 42% in 2nd and later-line CLDN18.2-positive advanced gastric/GEJ cancers in CLARITY-Gastric01

Topics ETFs

October 25, 2026

From AstraZeneca

TAGRISSO® (osimertinib) plus savolitinib reduced the risk of disease progression or death by 45% and the risk of death by 32% in MET-driven EGFR-mutated lung cancer after progression on TAGRISSO

October 25, 2026

From AstraZeneca

IMFINZI® (durvalumab) plus tarlatamab-dlle reduced the risk of death by 58% in 1st-line extensive-stage small cell lung cancer in the DeLLphi-305 Phase III trial

October 24, 2026

From AstraZeneca

Perioperative IMFINZI® (durvalumab) plus neoadjuvant enfortumab vedotin reduced risk of recurrence by 49% and risk of death by 42% in muscle-invasive bladder cancer

October 24, 2026

From AstraZeneca

ZEGFROVY® (sunvozertinib) now available in the US for patients with previously treated non-small cell lung cancer with EGFR exon 20 insertion mutations

October 22, 2026

From AstraZeneca

Alnylam Is Now Solidly Profitable. Why Are Investors Treating It Like a Broken Biotech? ↗

October 21, 2026

This beaten-down biotech has a better story than its stock chart suggests.

TEZSPIRE positive results from Phase III CROSSING trial in eosinophilic esophagitis including symptom improvement, histologic and endoscopic remission presented at United European Gastroenterology Week

October 20, 2026

From AstraZeneca

AstraZeneca to present overall survival data from four pivotal Phase III trials in Presidential Symposia at ESMO 2026 featuring Sone-Ve, IMFINZI® (durvalumab), TAGRISSO® (osimertinib) and savolitinib

October 19, 2026

From AstraZeneca

Astrazeneca (NYSE:AZN) presented Phase III data for efzimfotase alfa, an investigational enzyme replacement therapy for hypophosphatasia (HPP), at the American Society for Bone and Mineral Research...

AstraZeneca HPP Drug Shows Gains Despite Missing Key Phase III Endpoint ↗

October 12, 2026

The sell-offs for both of these beaten-down biotech stocks appear to be overdone.

Topics ETFs

Alnylam vs. Ionis: Here's the Better Bad-News Buy ↗

October 10, 2026

Grail and Veeva Systems could be well insulated from near-term headwinds.

2 Growth Stocks to Buy in October ↗

October 08, 2026

AstraZeneca opens new global strategic R&D center in Kendall Square, Cambridge, Massachusetts

October 05, 2026

From AstraZeneca

Wall Street expects an even bigger rebound for this beaten-down biotech stock.

18 of 21 Analysts Still Think Alnylam Stock Is a Buy. Here's Why They're Right. ↗

September 28, 2026

Perioperative IMFINZI® (durvalumab) plus neoadjuvant enfortumab vedotin granted Priority Review in the US for patients with muscle-invasive bladder cancer

September 25, 2026

From AstraZeneca

Analysts think Alnylam could rebound strongly over the next 12 months.

Alnylam's Sell-Off Looks Ugly -- but Wall Street Still Sees a Much Brighter Picture ↗

September 15, 2026

ENHERTU® (fam-trastuzumab deruxtecan-nxki) demonstrated a median progression-free survival of 14.3 months as 1st-line therapy in patients with HER2-mutant advanced non-small cell lung cancer in DESTINY-Lung04 Phase III trial

September 13, 2026

From AstraZeneca

TAGRISSO® (osimertinib) demonstrated unprecedented eight-year landmark survival in early-stage EGFR-mutated lung cancer in ADAURA Phase III trial

September 13, 2026

From AstraZeneca

Astrazeneca (NYSE:AZN) presented Phase III data for tozorakimab in chronic obstructive pulmonary disease, or COPD, at the 2026 European Respiratory Society Congress in Barcelona, reporting...

AstraZeneca COPD Drug Cuts Exacerbations as FDA Priority Review Nears ↗

September 13, 2026

IMFINZI® (durvalumab) plus tarlatamab demonstrated a statistically significant and highly clinically meaningful improvement in overall survival and progression-free survival in 1st-line extensive-stage small cell lung cancer

Topics ETFs

September 08, 2026

From AstraZeneca

Tozorakimab demonstrated statistically significant and highly clinically meaningful reduction in COPD exacerbations in OBERON and TITANIA Phase III trials

September 08, 2026

From AstraZeneca

ETCAMAH® (camizestrant) in combination with a CDK4/6 inhibitor approved in the US for 1st-line advanced HR-positive breast cancer

September 04, 2026

From AstraZeneca

This biotech stock looks like a great candidate to buy on the admittedly steep dip.

Here's Why Ionis Pharmaceuticals' Steep Sell-off Was Overdone ↗

September 03, 2026

AstraZeneca completes global license agreement for oral EGFR inhibitor ZEGFROVY® (sunvozertinib) for lung cancer

September 01, 2026

From AstraZeneca

Opinion: Bristol Myers Squibb Is a Buy -- but the Real Reason Why Might Surprise Investors ↗

August 29, 2026

Bristol Myers Squibb is facing down a major patent cliff, which is a problem and a huge motivating force.